FY2025 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreased by Analyst

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $0.93 per share for the year, down from their prior forecast of $0.94. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

A number of other research analysts have also weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 9th. JMP Securities reiterated a “market outperform” rating and set a $42.00 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Oppenheimer reiterated a “market perform” rating and set a $25.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, February 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 10th. Finally, Royal Bank of Canada dropped their price target on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $35.82.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $16.74 on Tuesday. The company has a market cap of $2.76 billion, a P/E ratio of -44.05 and a beta of 0.37. The stock has a 50 day simple moving average of $20.64 and a two-hundred day simple moving average of $23.72. ACADIA Pharmaceuticals has a fifty-two week low of $16.60 and a fifty-two week high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). The firm had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm’s revenue for the quarter was up 69.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) EPS.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,790 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the sale, the insider now directly owns 13,100 shares in the company, valued at approximately $234,097. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider James Kihara sold 1,790 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the completion of the sale, the insider now directly owns 13,100 shares of the company’s stock, valued at $234,097. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephen Davis sold 5,577 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.67, for a total transaction of $137,584.59. Following the transaction, the chief executive officer now directly owns 101,890 shares in the company, valued at $2,513,626.30. The disclosure for this sale can be found here. Insiders have sold 69,383 shares of company stock valued at $1,291,362 over the last quarter. 27.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. RTW Investments LP boosted its position in ACADIA Pharmaceuticals by 18.3% during the third quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock worth $241,255,000 after purchasing an additional 1,793,288 shares in the last quarter. Norges Bank acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $45,187,000. Fred Alger Management LLC raised its position in shares of ACADIA Pharmaceuticals by 38.7% during the 3rd quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company’s stock valued at $64,789,000 after buying an additional 867,818 shares during the period. Eventide Asset Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at approximately $25,342,000. Finally, M&G Investment Management Ltd. acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at about $10,349,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.